ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
"Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHER2-overexpressing (3+) breast cancer exhibits distinct clinicopathological characteristics compared to HER2 1+ and 2+ tumors; however, differences in their molecular features remain poorly defined. This study aimed to investigate clinicopathologic and somatic alterations in breast tumors stratified by HER2 status. MATERIALS AND
methodsNinety breast cancer patients were stratified by HER2 expression (1+, 2+, 3+) using immunohistochemistry and confirmed by FISH. For each patient, paired diagnostic biopsies and post-neoadjuvant chemotherapy (NACT) residual tumors were analyzed. Targeted next-generation sequencing (NGS) was performed on 34 paired samples, and shortlisted variants were validated by digital droplet PCR (ddPCR) in 90 cases.
resultAmong the 90 paired samples, 40 were HER2-high, and 50 were HER2-low/TNBC. HER2-high tumors presented with a larger mean size (3.34 cm vs. 2.29 cm) but lower lymph-node metastasis (40% vs. 60%) compared to HER2-low/TNBC. NGS identified frequent mutations in PIK3CA (24%), TP53 (32%), and ERBB2 (9%). PIK3CA variants His1047Arg and Glu542Lys exhibited significantly higher variant allele frequencies in post-NACT tumors (p < 0.05). HER2-high tumors demonstrated a greater prevalence of ERBB2 mutations (13.5%), whereas in HER2-low patients, such mutations appeared only after neoadjuvant chemotherapy (NACT). Importantly, PIK3CA mutations were correlated with increased lymph-node metastasis (p = 0.04) and poorer survival outcomes, underscoring their prognostic impact.
conclusionHER2-high and HER2-low/TNBC breast cancers demonstrate distinct clinicopathologic and molecular profiles. Therapy-associated enrichment of PIK3CA mutations and their association with aggressive behavior underscore their prognostic and therapeutic significance in HER2-positive disease. Further studies are needed to clarify their role in guiding personalized treatment strategies.
Indexed as
Identifiers
41548171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.